We stand today at the crossroads of a global challenge without precedent that demands researchers, policymakers, and governments address multiple dimensions which go far beyond the ramifications of the COVID-19 pandemic. And, while vaccines have transformed public health, particularly since national programs for immunization first became properly established and coordinated in the1960s, their traditional development typically requires years of research and efficacy and safety testing before reaching the clinic. But, 2020 saw a seismic shift in drug development paradigms as scientists embarked on a race to produce safe and effective coronavirus vaccines in record time.
What have we gleaned along this journey, when and where do we seek answers for the myriad of emerging ethical dilemmas? How do we leverage leanings for improving public health measures and outcomes? What are the implications for future drug development processes?
The Conversations with the Academy platform, under the aegis of the IFAPP Academy’s Value-Added Program offerings, explores this burgeoning medical, socio-economic, and ethical conundrum.
Our sincere appreciation for the perceptive opinions from our expert faculty and hosts. And, we remain encouraged by your continued patronage of the IFAPP Academy’s initiatives.
Click the below links to learn more about these webinars:
